<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927443</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_17_21</org_study_id>
    <nct_id>NCT03927443</nct_id>
  </id_info>
  <brief_title>A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Multi-Center, Evaluator -Masked, Randomized, Parallel Group, Active Controlled, Comparative Study of SPARC's SDP-133 Once Daily Compared With Lumigan Â® 0.01% (Bimatoprost Ophthalmic Solution) in Subjects With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Global FZE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Global FZE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of
      bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    [Sponsors decision]
  </why_stopped>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Actual">July 8, 2019</completion_date>
  <primary_completion_date type="Actual">July 8, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intra-ocular pressure (study eye)</measure>
    <time_frame>Week 12.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-matched change from baseline mean Intra-ocular pressure (study eye)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched percent change in Intra-ocular pressure (study eye)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 13</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDP-133</intervention_name>
    <description>one drop</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumigan</intervention_name>
    <description>one drop</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be male or female, of 18 years of age or older

          2. Provide signed and dated informed consent in accordance with good clinical practice
             (GCP) and local legislation prior to any study procedure.

          3. Have open-angle glaucoma, (with or without pseudo exfoliation, pigment dispersion
             component) or ocular hypertension in both eyes and likely to be controlled on
             monotherapy.

          4. Females of childbearing potential must not be pregnant or lactating (as confirmed by a
             negative urine pregnancy test Women of childbearing potential must agree to the use of
             a reliable method of contraception (e.g., total abstinence, intrauterine device, a
             double-barrier method [such as condom plus diaphragm with spermicide], oral,
             transdermal, injected or implanted non- or hormonal contraceptive), throughout the
             study. A sterile sexual partner is not considered an adequate form of birth control.
             Subjects on hormonal contraceptives must have been on the same hormonal contraceptive
             for at least one month before the Screening and continue throughout the duration of
             the study. A female is considered of childbearing potential if she has had her first
             menses and she is either

               1. not postmenopausal for at least 12 consecutive months prior to enrollment;(Visit
                  1) or

               2. not surgically sterilized by bilateral tubal ligation, or bilateral oophorectomy,
                  or hysterectomy

          5. Male subjects with partners of childbearing potential who are not using birth control
             as described above must use a barrier method of contraception (eg. Condom) if not
             surgically sterile (ie, vasectomy).

          6. Be able and willing to follow study instructions and complete all required visits.

        Exclusion Criteria:

          1. In the opinion of the investigator have uncontrolled or unstable systemic disease (eg,
             diabetes) which might interfere with the study. Subjects with a history of cancer or
             requiring cancer treatment within the past 5 years. Basal Cell and its treatment are
             allowed.

          2. Current or history of subjects with depression, cerebral or active coronary
             insufficiency or orthostatic hypotension.

          3. (If female of childbearing potential) Be pregnant, nursing, or planning a pregnancy
             from study entry and through the duration of the study.

          4. In the opinion of the investigator the subject has clinically relevant, abnormally low
             or high blood pressure or pulse rate.

          5. Have any known allergy or sensitivity to the study medications or their components.

          6. Have any contraindications to bimatoprost therapy.

          7. Be enrolled in an investigational drug or device study or have participated in such a
             study within 30 days prior to Visit 1.

          8. Subject who may be involved in any aspect of the trial conduct, may not be an
             investigator, sub-investigator, or other site staff , or related to any site staff.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

